Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zolpidem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.97 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.97 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.97 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.97 |
| ▸ | ALB | P02768 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.97 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | TSPO | P30536 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolpidem SCHEMBL80516 | 0.99 | GABRB2 (1.00) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL5606185 | 0.99 | GABRB2 (1.00) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL2064875 | 0.97 | GABRB2 (0.97) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL5766080 | 0.97 | GABRB2 (0.97) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL28035123 | 0.97 | GABRB2 (0.97) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL15169819 | 0.97 | GABRB2 (0.97) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL28577249 | 0.97 | GABRB2 (0.97) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL2064446 | 0.96 | GABRB2 (0.95) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL5629758 | 0.96 | GABRB2 (0.95) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL29033236 | 0.95 | GABRB2 (0.93) | GABRB2GABRA1ALBOPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008155620-A1 | DOSAGE FORM CONTAINING DISPERSIBLE MATRIX OF SUSTAINED RELEASE GRANULES | DEVELCO PHARMA SCHWEIZ AG (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1163241-B1 | ZOLPIDEM SALTS | SYNTHON BV (NL) | 2005-06-15 | — | — | EP | claimed |
| US-20040047908-A1 | Modified released formulations containing a hypnotic agent | LEMMENS JACOBUS M (NL) | 2004-03-11 | — | — | US | claimed |
| US-6638535-B2 | Pellet containing zolpidem in carrier; sustained release | SYNTHON BV (NL) | 2003-10-28 | — | — | US | claimed |
| US-20030054041-A1 | Modified release formulations containing a hypnotic agent | SYNTHON IP INC. | 2003-03-20 | — | — | US | claimed |
| EP-1272181-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | Synthon B.V. (NL) | 2003-01-08 | — | — | EP | claimed |
| EP-1163241-A1 | ZOLPIDEM SALTS | Synthon B.V. (NL) | 2001-12-19 | — | — | EP | claimed |
| WO-2001078725-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | SYNTHON B.V. (NL) | 2001-10-25 | — | — | WO | claimed |
| US-6242460-B1 | DOES NOT EXHIBIT A MELTING ENDOTHERM THAT CORRESPONDS TO ZOLPIDEM FREE BASE. | SYNTHON BV (NL) | 2001-06-05 | — | — | US | claimed |
| WO-2000058310-A1 | ZOLPIDEM SALTS | SYNTHON B.V. (NL) | 2000-10-05 | — | — | WO | claimed |
| CN-114057725-A | Synthetic method of zolpidem tartrate | 株洲千金药业股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114057726-A | Synthetic method of zolpidem hydrochloride | 株洲千金药业股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114008023-A | Crystal form of Sopyrazamine and preparation method thereof | 科研制药株式会社 | 2022-02-01 | — | — | CN | disclosed |
| US-8148393-B2 | Zolpidem tablets | SYNTHON BV (NL) | 2012-04-03 | — | — | US | disclosed |
| EP-1948132-B1 | ZOLPIDEM TABLETS | SYNHTON B V (NL) | 2009-08-05 | — | — | EP | disclosed |
| US-20030054041-A1 | Modified release formulations containing a hypnotic agent | SYNTHON IP INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1272181-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | Synthon B.V. (NL) | 2003-01-08 | — | — | EP | disclosed |
| EP-1163241-A1 | ZOLPIDEM SALTS | Synthon B.V. (NL) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001078725-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | SYNTHON B.V. (NL) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000058310-A1 | ZOLPIDEM SALTS | SYNTHON B.V. (NL) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054041-A1 | Modified release formulations containing a hypnotic agent | CRH, HTR7, MCHR1 | GABRA1 97/4885GABRB1 305/4885GABRG2 170/4885 |
| US-20040047908-A1 | Modified released formulations containing a hypnotic agent | CRH, HTR7, MCHR1 | GABRA1 107/4885GABRB1 352/4885GABRG2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.